Barclays Maintains Overweight on AbbVie, Raises Price Target to $195
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $185 to $195.
March 27, 2024 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on AbbVie and raises the price target from $185 to $195.
The upgrade in price target by Barclays, a major financial institution, reflects a positive outlook on AbbVie's stock. This is likely to instill confidence among investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100